# TIQ-15: A Novel CXCR4 Antagonist with Dual Tropic HIV Entry Inhibition

**ID:** TROP-003
**Year:** 2024
**Journal:** PLOS Pathogens
**DOI:** [10.1371/journal.ppat.1012448](https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1012448)
**PubMed:** [39146384](https://pubmed.ncbi.nlm.nih.gov/39146384/)

---

## Abstract

This August 2024 study characterizes TIQ-15, a novel tetrahydroisoquinoline CXCR4 antagonist with unique dual tropic HIV entry inhibition properties. TIQ-15 potently blocks X4-tropic HIV with IC50 of 13 nM while demonstrating synergistic activity when combined with the CCR5 antagonist maraviroc, offering a potential solution for treating patients with mixed-tropism virus.

---

## Key Concepts

- **TIQ-15**: Tetrahydroisoquinoline-based CXCR4 antagonist
- **Allosteric Mechanism**: Novel binding site on CXCR4
- **Receptor Internalization**: Drug-induced CXCR4 downregulation
- **Dual Tropism**: Activity against both X4 and R5 viruses

---

## The Unmet Need

### Current Landscape
| Factor | Situation |
|:-------|:----------|
| CCR5 antagonist | Maraviroc (approved 2007) |
| CXCR4 antagonist | **None approved for HIV** |
| X4 emergence | ~50% of late-stage patients |
| Clinical gap | Major unmet need |

> "Approximately 50% of late-stage HIV patients develop CXCR4-tropic virus, making clinical anti-HIV CXCR4 antagonists needed."

---

## TIQ-15 Pharmacology

### Mechanism of Action
```
TIQ-15 binding → Allosteric site on CXCR4 →
CXCR4 internalization → Blocked X4 viral entry
(CD4 levels unaffected)
```

### Key Features
| Property | Details |
|:---------|:--------|
| Mechanism | Allosteric CXCR4 antagonism |
| Receptor effect | Induces CXCR4 internalization |
| CD4 effect | None (preserved) |
| Binding site | Novel allosteric region |

> "TIQ-15 induces CXCR4 receptor internalization without affecting the levels of the CD4 receptor."

---

## Antiviral Potency

### Overall Activity
| Tropism | IC50 | Efficacy |
|:--------|:-----|:---------|
| X4-tropic | **13 nM** | Potent |
| Dual-tropic | Low nM | Potent |
| R5-tropic | Higher | Moderate |

### Activity Against Clinical Isolates
| Isolate | Tropism | IC50 |
|:--------|:--------|:-----|
| 92UG046 | X4 | **0.78 nM** |
| CMU02 | X4 | **2.16 nM** |
| 93BR020 | Dual | **1.08 nM** |
| R5 isolates | R5 | Moderate inhibition |

> "TIQ-15 inhibited HIV-1 differently depending on viral tropisms, with the strongest inhibition against the X4-tropic isolates."

---

## Synergy with Maraviroc

### Combination Studies
| Finding | Significance |
|:--------|:-------------|
| Co-dosing with maraviroc | Synergistic activity |
| Mixed tropism coverage | Comprehensive protection |
| Low-level anti-R5 activity | Unexpected bonus |

### Clinical Implications
> "TIQ-15 could potentially be co-dosed with the CCR5 inhibitor maraviroc to block viruses of mixed tropisms."

---

## Drug-Like Properties

### ADME Profile
| Parameter | Value | Assessment |
|:----------|:------|:-----------|
| Metabolic liability | Low | Favorable |
| Oral bioavailability | **63%** | Good |
| Cytotoxicity | Not detected | Safe |

### In Vivo Effects
| Observation | Details |
|:------------|:--------|
| White blood cell mobilization | Dose-dependent |
| Mechanism | CXCR4 antagonism on hematopoietic cells |
| Safety | Well-tolerated |

---

## Comparison with Existing Drugs

### Entry Inhibitors Landscape
| Drug | Target | Tropism Coverage |
|:-----|:-------|:-----------------|
| Maraviroc | CCR5 | R5 only |
| AMD3100 (plerixafor) | CXCR4 | X4 (not HIV-approved) |
| **TIQ-15** | **CXCR4** | **X4 + dual (+ some R5)** |
| Enfuvirtide | gp41 | All tropisms |

---

## Future Development

### Path to Clinical Use
1. Further preclinical optimization
2. Phase I safety studies
3. Combination trials with maraviroc
4. Late-stage HIV patient population

### Potential Applications
| Setting | Rationale |
|:--------|:----------|
| Tropism switch | Patients developing X4 virus |
| Pre-emptive use | High-risk patients |
| Combination therapy | Standard of care enhancement |

---

## Relevance to Project

TIQ-15 research informs the Ternary VAE project:
- **V3 sequence-tropism**: Understanding drug-tropism relationships
- **Resistance prediction**: Mutations affecting CXCR4 binding
- **Fitness landscapes**: Tropism as selectable phenotype
- **Drug design**: Sequence-based inhibitor optimization

---

*Added: 2025-12-24*
